We choose to enter Poland first because this country is located in Central Europe, so it can become a hub to enter other markets around it.Jakarta (ANTARA) - An Indonesian pharmaceutical company, PT Ferron Par Pharmaceuticals has entered the Polish market with the initial export of its diabetes medicine named Avamina SR®.
"We choose to enter Poland first because this country is located in Central Europe, so it can become a hub to enter other markets around it," Director of PT Ferron Par Pharmaceuticals, Krestijanto Pandji said in Cikarang, Bekasi, West Java Tuesday.
Avamina SR® is a product with the same active substance as Glucient® SR products that have been exported by Ferron to the United Kingdom (UK) and the Netherlands, and it is also marketed in Indonesia with a name, Glumin XR.
Poland is Ferron's third export destination in Europe, after Britain and the Netherlands. Ferron that belongs to Dexa Group sent as many as five million Avamina tablets for its initial export.
"This year we are targeting 15 million tablets to be exported to Poland," Pandji stated.
Entering European markets has been challenging, particularly in term of understanding the complex language of European countries as well as competing with pharmaceutical products from Western Europe and Russia, he admitted.
With the export to Poland, Ferron has increased its export target from 11 percent to 20 percent this year.
Pandji expressed hope that the Ferron's export to Poland will contribute more foreign exchange to the country and strengthen trade cooperation between Indonesia and Poland, especially for high-tech products.
Poland is one of the countries which has a highly regulated market for pharmaceutical products.
Related news: Indonesia to augment sales of medicines, medical devices in Africa
Related news: UN Chief: Some 422 m. people live with diabetes
Related news: Jokowi invites Indian businessmen to invest in pharmaceutical industry
Translator: Sella Panduarsa Gareta, Yuni A
Editor: Sri Haryati
Copyright © ANTARA 2019
